- Report
- August 2025
- 186 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- October 2025
- 185 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- October 2025
- 194 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- October 2025
- 180 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- November 2025
Global
From €4355EUR$4,900USD£3,800GBP
- Report
- November 2025
Global
From €4355EUR$4,900USD£3,800GBP
- Report
- October 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- March 2025
- 200 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- February 2025
- 200 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- November 2025
- 181 Pages
Global
From €3999EUR$4,500USD£3,490GBP
- Report
- November 2025
- 184 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- November 2025
- 200 Pages
Global
From €5653EUR$6,360USD£4,933GBP
€7066EUR$7,950USD£6,166GBP
- Drug Pipelines
- April 2025
- 90 Pages
Global
From €1422EUR$1,600USD£1,241GBP
€1778EUR$2,000USD£1,551GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1422EUR$1,600USD£1,241GBP
€1778EUR$2,000USD£1,551GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1422EUR$1,600USD£1,241GBP
€1778EUR$2,000USD£1,551GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more